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Healthcare workers (HCWs) have one of the highest rates of occupational risk for hepatitis B virus (HBV) infection worldwide. [1] [2] [3] While a vaccine for HBV exists, its utilization among HCWs and the factors surrounding its utilization in many developing countries, such as Georgia, are unknown.
The World Health Organization (WHO) has classified Georgia as a country with a high prevalence of HBV infection. 4 A study of Georgian blood donors revealed an HBV infection prevalence estimate (3.4% of donors tested positive for HBV surface antigen [HBsAg] ) that was higher than national prevalence estimates in neighboring countries, 5 and on the basis of reports from the National Center for Disease Control and Public Health of Georgia, HBV incidence has increased gradually since 2002.
Despite the introduction of a safe and effective HBV vaccine in 2000, this vaccine is still consistently underutilized among the adult population of Georgia, including those at high risk for contracting HBV infection. Low vaccination coverage has been partially explained by negative attitudes toward the vaccine among HCWs, who are more knowledgeable about vaccine-preventable diseases than the general population and are perceived as role models for health behavior.
methods

Study Design and Sample
A cross-sectional study of the prevalence and awareness of bloodborne viruses among randomly selected HCWs employed by 2 large hospitals in Batumi and Kaspi, Georgia, was conducted in 2007. Study participants were selected by means of simple random sampling from the list of eligible full-time physician and nursing staff in the services of internal medicine, obstetrics, surgery, intensive care, or pediatrics until each hospital's predetermined sample size of approximately 150 HCWs was met. The slight variation in sample size oc-curred as a result of batch recruitment of randomly selected individuals.
Enrollment and Data Collection
After informed consent was obtained, participating HCWs completed a self-administered survey on knowledge, attitudes, and practices regarding exposure to and protection from bloodborne pathogens. In addition, HCWs were asked to provide blood to be tested for HBV, hepatitis C virus (HCV), and human immunodeficiency virus. To maintain confidentiality, a code was used to link HCW data, and a study physician reported blood test results in person to study participants. Referrals for medical care were provided when needed. Ethics committee approval for the study was obtained from the Georgian Rehabilitation Center.
The survey contained questions about demographic and professional characteristics, awareness of HBV and risk factors for exposure to bloodborne pathogens, attitudes toward infected patients and vaccines, and prevention methods. To assess openness to vaccination for HBV, individuals were asked about their HBV vaccination status and their attitude toward recommending HBV vaccine to other HCWs.
The reasons for receiving HBV vaccination and willingness to recommend such vaccination to other HCWs were explored. Factors assessed with the survey included fear of vaccine-related side effects, misconceptions about vaccine effectiveness, concern about vaccine expense, and low perceived risk of contracting HBV infection. Other risk factors for lack of universal HCW vaccination were studied independently and considered as potential confounders for the main research questions. These included age, duration of employment, occupation (physician or nurse), and specialization.
Laboratory Tests
Venous blood samples (2-3 mL) were collected and transported daily from the hospitals to Tbilisi for storage and analysis. To estimate the seroprevalence of HBV, serum was tested for HBsAg and anti-HBc in the laboratory of the rehabilitation center by use of a third-generation enzyme-linked immunosorbent assay method. All HBsAg-positive serum samples were further investigated with the use of confirmatory assays; immunoreaction of neutralization combined with the HBsAg assay was used to confirm the presence of HBsAg.
Statistical Analysis
Data were checked for completeness and consistency, doubleentered into SPSS, version 13.0 (SPSS), and verified, then exported to SAS (SAS Institute) for analysis. Bivariate analyses were performed to estimate the prevalence ratios (PRs), with 95% confidence intervals (CIs), between predictive factors for vaccination and willingness to recommend the HBV vaccine to other HCWs. Multivariate analysis was performed using Poisson regression with robust variance estimators to identify the strongest predictive factors related to vaccination or recommendation to receive vaccination. 6 Multivariate descriptive analysis was conducted to identify potential interactions, and interaction terms were then added to the model for assessment. Confounding was assessed by examining changes in the estimated association between the strong predictive factors and outcome upon removal of potential confounders. Model fit was assessed overall and by comparing the observed proportion of the outcome with the predicted proportion, within each covariate pattern.
results
Participant Sample
Of the 325 randomly selected HCWs, 310 (95%) enrolled in the study, and 297 (91%) provided sufficient information for inclusion in the analyses. . Overall, 171 of 297 (58%) HCWs were at risk for infection; 126 (42%) HCWs were not at risk because either they had been vaccinated before exposure to infection (27 [9%] ) or had already been exposed to infection (99 [33%] were anti-HBc positive). The latter category includes 10 (3%) HCWs who had received vaccination after they were exposed to infection (vaccinated and anti-HBc positive).
Vaccinated and Recommend Vaccination: Bivariate Analyses
While only 37 (12%) of the 297 HCWs had been vaccinated against HBV, 161 HCWs (54%) reported that they would recommend vaccination to colleagues. HCWs younger than 40 years of age were more likely to be vaccinated than older HCWs ( Table 1) .
The strongest predictor of vaccine acceptance and willingness to recommend vaccination was concern about HBV vaccine safety and adverse events. Of the 213 (72%) HCWs who considered the HBV vaccine safe, 150 (70%) would recommend vaccination, compared with only 11 (13%) of the 84 note. CI, confidence interval; PR, prevalence ratio. a The survey question was: "How many of your colleagues do you think have received HBV vaccination?" b The survey questions were: "Do you agree that the HBV vaccine is safe?" "How common is post-HBV vaccination complication (local soreness, mild to moderate fever, allergic reaction, demyelinating disease including autism, and reactivation of multiple sclerosis)?" "Are you (HCWs) under more risk of HBV infection than the rest of the population?" Predictors of having received vaccination that were identified through bivariate analysis included having colleagues who had been vaccinated and the perceived safety of the vaccine. Interestingly, those who believed that HCWs were not at greater risk of HBV infection than the general population were more likely to have received vaccination than those who believed that HCWs were at greater risk than the general population (PR, 2.1 [95% CI, 1.1-4.0]).
Multivariate Analyses
Regression analyses identified several important predictors of vaccine recommendation and vaccine acceptance. Multivariate analyses for recommending vaccination to other HCWs highlighted the importance of HCWs' perception of safety of the HBV vaccine, including concerns about both the vaccine's overall safety and the risk of adverse events. An interaction between perceived safety of the vaccine, perceived risk of adverse events, and perceived risk of HBV infection for HCWs was identified. HCWs universally recommended HBV vaccination for other HCWs if they believed that the vaccine was safe and not associated with adverse events and that HCWs were at higher risk of infection than the general population. Conversely, those who believed that the vaccine was safe but believed that adverse events might occur were less likely to recommend vaccination for other HCWs unless they believed that HCWs were at higher risk for HBV infection than the general population. Of the 84 HCWs who thought the vaccine was not safe, only 11 (13%) would recommend vaccination for other HCWs ( Table 2) .
Understanding of factors related to vaccination was limited as a result of the relatively low rate of vaccination among HCWs. The most important factor related to vaccination was younger age, which is consistent with the findings of the bivariate analyses.
The final models were assessed for potential confounding so that the adjusted prevalence ratios could be interpreted; no confounders were identified beyond the factors included in the final model. Assessment of model fit was conducted by assessing the difference between observed and predicted values for each covariate pattern. Overall, the fit was reasonable and, in general, the model slightly overestimated the proportion of HCWs who would not recommend vaccination to other HCWs. The measures of association had little error due to modeling.
Barriers to HBV Vaccination among HCWs
Questions designed to identify important barriers to increasing the rate of vaccination in the healthcare workforce revealed that 196 of 297 (66%) HCWs thought that providing free or low-cost vaccination was important, as was providing data on the occupational risk of HBV. [7] [8] [9] but far below that of most developed countries, where typically about three-quarters of HCWs are vaccinated against HBV. [10] [11] [12] [13] The prevalence of seropositivity for anti-HBc (33%) among HCWs was higher than estimates of previous HBV infection prevalence among the general population in Georgia (20%), 14 which suggests some occupational risk. The occupational risk may be due to low rates of vaccination coverage, lack of consistent supplies (eg, gloves), and lack of procedures used to reduce the risk of transmission of bloodborne pathogens (eg, avoidance of manually recapping used needles).
A primary barrier to increasing the rate of vaccination against HBV among Georgian HCWs is their concern about vaccine safety. While both the plasma and recombinant HBV vaccines are considered safe, [15] [16] [17] [18] [19] [20] [21] 28% of HCWs surveyed believed that HBV vaccines were unsafe. Data from the US Vaccine Adverse Event Report System and Vaccine Safety Datalink Project, [22] [23] [24] the Canadian Adverse Events Following Immunization database, and adverse event reporting systems in other countries suggest that serious health events temporally linked to the vaccine occur only rarely. [25] [26] [27] [28] [29] [30] The most common adverse reactions reported include localized soreness at the injection site and low-grade fever of short duration. 31 Other far less commonly reported adverse events (reported by fewer than 1% of respondents) include fatigue, headache, malaise, nausea, dizziness, skin rash, arthralgia, and myalgia. Health events temporally linked to vaccination, including anaphylaxis and neurologic events (in particular, demyelinating neuropathies, such as multiple sclerosis) have been reported to vaccine adverse events systems, but despite multiple investigations, statistical associations with receipt of the vaccine have not been found. 32, 33 However, the rarity of these events may limit the ability to fully understand the relationship between the HBV vaccine and serious adverse events that may occur in fewer than 1 in 1 million vaccinations.
The elevated concern about HBV vaccine safety in Georgia is widely thought to be related to a highly publicized adverse event that occurred in 2002: the abrupt onset of encephalomyelitis in a 12-year-old boy after vaccination against HBV. The short time interval between vaccination and the onset of symptoms led some health professionals to believe that this was a vaccine-related adverse event. A lawsuit filed against the Georgian government and the provider and manufacturer of the vaccine to cover the medical expenses of the boy provided another round of publicity about the perceived harm of the HBV vaccine. An investigation conducted by the WHO concluded that there was no link between the vaccine and the reported adverse event. However, because the WHO had provided a quality certificate to the manufacturer of the vaccine, the WHO findings were largely discounted by the Georgian public. 34 Given the general public concern about vaccine safety worldwide, risk communication becomes an important element in a vaccination campaign so that HCWs can make an informed choice. It is clear that stating "the HBV vaccine is safe" is insufficient communication for Georgian HCWs. More nuanced and detailed communication is needed. For example, the US Centers for Disease Control and Prevention fact sheets about the HBV vaccine reveal a progression from general to detailed information:
2006: "Scientific data show that hepatitis B vaccines are very safe for infants, children, and adults. There is no confirmed evidence which indicates that hepatitis B vaccine can cause chronic illnesses." The latter approach opens the door for dialogue and, when combined with disease data, provides an opportunity to consider the risks and benefits of vaccination. In Georgia, the WHO investigation's conclusion was not valued because it discounted the possibility that a severe adverse event happened that HCWs could see and evaluate for themselves. In this case, oversimplistic communication about risk backfired. The vaccine safety questions that have emerged in recent years underscore the need for vaccination campaigns to be articulated with clear, effective risk-benefit messages based on data specific to the recipients' region, occupation, and other sociodemographic factors.
The strongest predictive factor for being vaccinated was lower age. Other factors predictive of recommending HBV vaccination for other HCWs were having received vaccination, having several colleagues who had received vaccination, and perception that the risk of infection was higher than for the general population.
The vaccination campaign must also balance ethics and economics. Approximately 42% of HCWs who participated in this study did not need HBV vaccination because of previous vaccination or infection. On a national scale, this would translate to thousands of unnecessary vaccine doses if all HCWs were vaccinated. On the other hand, laboratory testing for evidence of previous exposure might be difficult to administer and increase the cost of the campaign. In Turkey, some hospitals routinely test new HCWs and vaccinate those who do not have an immune response to HBV. 35, 36 In Georgia, this approach could be problematic because of fears of discrimination and job loss if a positive result was obtained.
As with any cross-sectional survey, our study's limitations included factors that may affect generalizability or bias estimates. Only physicians and nurses were selected to participate; thus, we do not have information on a large group of ancillary HCWs, such as laboratory workers, phlebotomists, and housekeepers, who are also at risk of contracting HBV. 37, 38 The reasons for nonadherence to vaccination recommendations may be related to social issues, such as cost of vaccination, that have been underreported in the literature. Our survey relied on the participants' self-reported vaccination status and was not validated by means of medical records. The sample size was too small to assess effect modifiers related to vaccination status. Finally, this study was limited to 2 large hospitals with different vaccination coverage levels. A larger study that included more hospitals would help to identify hospital-level factors that may be important.
In Georgia, the overall prevalence of HBV is high, and it seems to be higher among HCWs. The risk-benefit ratio is clearly in favor of vaccination for HCWs. On the basis of results from this HCWs survey, vaccine education efforts to date have not responded adequately to concerns about vaccine safety. Georgia is planning a major HBV vaccination campaign among HCWs in 2009. The results of our study suggest several strategies for increasing vaccine acceptance. First, it is important to articulate a vaccine safety message appropriate for HCWs, especially more senior workers who are less likely to accept vaccination. Second, because knowing a vaccinated HCW increases the likelihood of acceptance, program coordinators should schedule vaccination recruitment with follow-up visits to complete the vaccination series. Third, vaccination should be provided free or at low cost. Fourth, a screening protocol should be adopted that provides HCWs with confidentiality and control of their HBV status while allowing for cost containment. Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.
